Terms: = Adult Hodgkin lymphoma AND BCL2, Bcl-2, 596, ENSG00000171791 AND Prognosis
142 results:
1. Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, bcl2, BCL6, and CCND1 rearrangements.
Monika F; Sabri A; Cantu D; Vail E; Siref A
J Hematop; 2024 Sep; 17(3):155-161. PubMed ID: 38914869
[TBL] [Abstract] [Full Text] [Related]
2. [Clinical study of mature B-cell lymphoma in 11 children with chromosome 11 long-arm abnormalities].
Zhang N; Duan YL; Zhou CJ; Jin L; Yang J; Huang S; Zhang M; Li N
Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):924-929. PubMed ID: 38185522
[No Abstract] [Full Text] [Related]
3. Tumor microenvironment in hodgkin lymphoma: novel prognostic factors for assessing disease evolution.
Turbatu A; Dobrea C; Stoian M; Barta CT; Halcu G; Birceanu A; Bordea AM; Ghimici CG; Oprea MM; Neacșu LD; Lupu AR; Coliță A
J Med Life; 2023 Aug; 16(8):1201-1210. PubMed ID: 38024830
[TBL] [Abstract] [Full Text] [Related]
4. Myc rearrangement and concurrent high protein expression of C-Myc/bcl2 carry an adverse prognosis in diffuse large B-cell lymphoma.
Wang X; He J; He H; Shuai Y; Wang L; Li Y; Huang Y; Yu K; Zhao M; Xie T; Li D
Ann Diagn Pathol; 2023 Oct; 66():152165. PubMed ID: 37348414
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
Li J; Tang X; Luo X; Liu L; Li D; Yang L
Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
[TBL] [Abstract] [Full Text] [Related]
6. Diffuse large B cell lymphoma CD5-positive arising in an immune deficiency and immune dysregulation setting: A case report and brief review of the literature.
Cristian M; Baz RA; Stoica AG; Așchie M; Ghinea MM; Deacu M; Boșoteanu M; Mitroi AF; Dobrin N; Iordache IE; Bălțătescu GI
Medicine (Baltimore); 2023 Feb; 102(8):e33083. PubMed ID: 36827036
[TBL] [Abstract] [Full Text] [Related]
7. Large B-cell lymphoma with IRF4 gene rearrangements: Differences in clinicopathologic, immunophenotypic and cytogenetic features between pediatric and adult patients.
Berg HE; Peterson JF; Lee HE; McPhail ED
Hum Pathol; 2023 Jan; 131():108-115. PubMed ID: 36470475
[TBL] [Abstract] [Full Text] [Related]
8. bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell lymphoma.
Luanpitpong S; Janan M; Yosudjai J; Poohadsuan J; Chanvorachote P; Issaragrisil S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430955
[TBL] [Abstract] [Full Text] [Related]
9. Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell lymphoma: A Possible Association with the prognosis of lymphoma.
Yan S; Shang Q; Fan Z; Yang Y; Liu Y; Gao H; Chen K; Liang F; Li X; Zhang Q; Yan H
J Immunol Res; 2022; 2022():5633096. PubMed ID: 36213322
[TBL] [Abstract] [Full Text] [Related]
10. [Nodular lymphocyte predominant hodgkin lymphoma (paragranuloma of Poppema) in children: Case report, review of the literature and treatment].
Wilgenhof K; Théate I; Devalck C; Forsyth R; Dehou MF
Ann Pathol; 2023 Jan; 43(1):39-44. PubMed ID: 36008237
[TBL] [Abstract] [Full Text] [Related]
11. Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.
Yuan CT; Chuang SS; Cheng PY; Chang K; Wang H; Tsai JH; Liau JY; Chou WC
J Pathol Clin Res; 2022 Sep; 8(5):436-447. PubMed ID: 35715938
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.
Chiappella A; Diop F; Agostinelli C; Novo M; Nassi L; Evangelista A; Ciccone G; Di Rocco A; Martelli M; Melle F; Moia R; Motta G; Righi S; Santambrogio E; Tucci A; Balzarotti M; Ladetto M; Pileri SA; Gaidano G; Vitolo U;
Br J Haematol; 2022 Mar; 196(5):1184-1193. PubMed ID: 34951009
[TBL] [Abstract] [Full Text] [Related]
13. Blastoid variant of mantle cell lymphoma in palatine tonsil.
Valente VB; de Castro TF; Takamiya AS; Callestini R; Xavier-Junior JCC; Cortopassi GM; Neto SC; Collado FU; Biasoli ÉR; Miyahara GI; Bernabé DG
Oral Oncol; 2021 Nov; 122():105552. PubMed ID: 34610523
[TBL] [Abstract] [Full Text] [Related]
14. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract] [Full Text] [Related]
15. Apoptotic regulator bcl-2 blockade as a potential therapy in classical hodgkin lymphoma.
Gamboa-Cedeño AM; Díaz M; Cristaldo N; Otero V; Schutz N; Fantl D; Cugliari S; Zerga M; Rojas-Bilbao E; Jauk F; García Rivello H; Nuñez M; Ranuncolo SM
Life Sci; 2021 Mar; 268():118979. PubMed ID: 33421528
[TBL] [Abstract] [Full Text] [Related]
16. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients.
Gouveia GR; Ferreira SC; Siqueira SAC; de Pádua Covas Lage LA; Hallack Neto AE; de Oliveira Costa R; Pereira J
BMC Cancer; 2020 Oct; 20(1):1041. PubMed ID: 33121489
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic significance of bcl-2 expression in primary cutaneous B-cell lymphoma: a reappraisal.
Pileri A; Agostinelli C; Bertuzzi C; Grandi V; Maio V; Lastrucci I; Santucci M; Pimpinelli N
Ital J Dermatol Venerol; 2021 Dec; 156(6):642-649. PubMed ID: 33070565
[TBL] [Abstract] [Full Text] [Related]
18. [Clinicopathological study of large B-cell lymphoma with IRF4 rearrangement].
Chen W; Gong QX; Li X; Song GX; Wang Z; Xu W; Zhang ZH
Zhonghua Bing Li Xue Za Zhi; 2020 Oct; 49(10):1003-1008. PubMed ID: 32992413
[No Abstract] [Full Text] [Related]
19. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications.
Pérez-Carretero C; Hernández-Sánchez M; González T; Quijada-Álamo M; Martín-Izquierdo M; Hernández-Sánchez JM; Vidal MJ; de Coca AG; Aguilar C; Vargas-Pabón M; Alonso S; Sierra M; Rubio-Martínez A; Dávila J; Díaz-Valdés JR; Queizán JA; Hernández-Rivas JÁ; Benito R; Rodríguez-Vicente AE; Hernández-Rivas JM
Int J Cancer; 2020 Nov; 147(10):2780-2792. PubMed ID: 32720348
[TBL] [Abstract] [Full Text] [Related]
20. Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma.
Badri N; Ngamdu KS; Torabi A; Guar S
J Cancer Res Ther; 2020; 16(1):183-185. PubMed ID: 32362635
[TBL] [Abstract] [Full Text] [Related]
[Next]
